Merck & Co., Inc. Accounts Receivable, Sale
Merck & Co., Inc. (MRK) reported Accounts Receivable, Sale of $1.60 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Credit Losses
us-gaap:AccountsReceivableSale · last filed 2026-08-07
- Merck & Co., Inc. accounts receivable, sale for the quarter ending 2026-06-30 was $1.60B.
- Merck & Co., Inc. accounts receivable, sale for the quarter ending 2026-03-31 was $1.60B, a 5.88% decline year-over-year.
- Merck & Co., Inc. accounts receivable, sale for the quarter ending 2025-12-31 was $1.60B, a 23.81% decline year-over-year.
- Merck & Co., Inc. accounts receivable, sale for the quarter ending 2025-09-30 was $1.70B, a 750.00% increase year-over-year.
- Merck & Co., Inc. accounts receivable, sale for fiscal 2025 was $1.60B, a 23.81% decline from fiscal 2024.
- Merck & Co., Inc. accounts receivable, sale for fiscal 2024 was $2.10B, a 30.00% decline from fiscal 2023.
- Merck & Co., Inc. accounts receivable, sale for fiscal 2023 was $3.00B, a 20.00% increase from fiscal 2022.
- Merck & Co., Inc. accounts receivable, sale for fiscal 2022 was $2.50B.
| Period end | Accounts Receivable, Sale 3 month | Accounts Receivable, Sale 3 month as first filed | Accounts Receivable, Sale 6 month | Accounts Receivable, Sale 9 month | Accounts Receivable, Sale 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.60B 10-Q · filed 2026-08-07 | $3.20B derived: sum of 2 quarters · filed 2026-08-07 | $4.80B derived: sum of 3 quarters · filed 2026-08-07 | $6.50B derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | $1.60B 10-Q · filed 2026-05-04 | $3.20B derived: sum of 2 quarters · filed 2026-08-07 | $4.90B derived: sum of 3 quarters · filed 2026-08-07 | $4.80B derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-12-31 | $1.60B 10-Q · filed 2026-08-07 | $3.30B derived: sum of 2 quarters · filed 2026-08-07 | $3.20B derived: sum of 3 quarters · filed 2026-08-07 | $1.60B 10-K · filed 2026-02-24 | |
| 2025-09-30 | $1.70B 10-Q · filed 2025-11-05 | $1.60B derived: sum of 2 quarters · filed 2025-11-05 | $3.30B derived: sum of 3 quarters · filed 2025-11-05 | $5.40B derived: sum of 4 quarters · filed 2025-11-05 | |
| 2025-06-30 | -$100.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.60B 10-Q · filed 2025-08-05 | $3.70B derived: sum of 3 quarters · filed 2025-11-05 | $3.90B derived: sum of 4 quarters · filed 2025-11-05 | |
| 2025-03-31 | $1.70B 10-Q · filed 2025-05-02 | $3.80B derived: sum of 2 quarters · filed 2025-11-05 | $4.00B derived: sum of 3 quarters · filed 2025-11-05 | $4.20B derived: sum of 4 quarters · filed 2025-11-05 | |
| 2024-12-31 | $2.10B 10-Q · filed 2025-11-05 | $2.30B derived: sum of 2 quarters · filed 2025-11-05 | $2.50B derived: sum of 3 quarters · filed 2025-11-05 | $2.10B 10-K · filed 2026-02-24 | |
| 2024-09-30 | $200.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $400.00M derived: sum of 2 quarters · filed 2024-11-06 | $3.10B 10-Q · filed 2024-11-06 | $2.60B derived: sum of 4 quarters · filed 2025-02-25 | |
| 2024-06-30 | $200.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $2.90B 10-Q · filed 2024-08-05 | $2.40B derived: sum of 3 quarters · filed 2025-02-25 | $3.00B derived: sum of 4 quarters · filed 2025-02-25 | |
| 2024-03-31 | $2.70B 10-Q · filed 2024-05-03 | $2.20B derived: sum of 2 quarters · filed 2025-02-25 | $2.80B derived: sum of 3 quarters · filed 2025-02-25 | $3.30B derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-12-31 | -$500.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $100.00M derived: sum of 2 quarters · filed 2025-02-25 | $600.00M derived: sum of 3 quarters · filed 2025-02-25 | $3.00B 10-K · filed 2025-02-25 | |
| 2023-09-30 | $600.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $1.10B derived: sum of 2 quarters · filed 2023-11-03 | $3.50B 10-Q · filed 2023-11-03 | $6.00B derived: sum of 4 quarters · filed 2023-11-03 | |
| 2023-06-30 | $500.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $2.90B 10-Q · filed 2023-08-07 | $5.40B derived: sum of 3 quarters · filed 2023-08-07 | $7.70B derived: sum of 4 quarters · filed 2023-08-07 | |
| 2023-03-31 | $2.40B 10-Q · filed 2023-05-05 | $4.90B derived: sum of 2 quarters · filed 2023-05-05 | $7.20B derived: sum of 3 quarters · filed 2023-05-05 | $9.10B derived: sum of 4 quarters · filed 2023-05-05 | |
| 2022-12-31 | $2.50B 10-K · filed 2023-02-24 | $4.80B derived: sum of 2 quarters · filed 2023-02-24 | $6.70B derived: sum of 3 quarters · filed 2023-02-24 | $2.50B 10-K · filed 2024-02-26 | |
| 2022-09-30 | $2.30B 10-Q · filed 2022-11-03 | $4.20B derived: sum of 2 quarters · filed 2022-11-03 | $6.40B derived: sum of 3 quarters · filed 2022-11-03 | $9.20B derived: sum of 4 quarters · filed 2023-02-24 | |
| 2022-06-30 | $1.90B 10-Q · filed 2022-08-05 | $2.50B 10-Q · filed 2023-05-05 | $6.90B derived: sum of 3 quarters · filed 2023-02-24 | $9.30B derived: sum of 4 quarters · filed 2023-02-24 | |
| 2022-03-31 | $2.20B 10-Q · filed 2022-05-05 | $5.00B derived: sum of 2 quarters · filed 2023-02-24 | $7.40B derived: sum of 3 quarters · filed 2023-02-24 | $9.80B derived: sum of 4 quarters · filed 2023-02-24 | |
| 2021-12-31 | $2.80B 10-K · filed 2023-02-24 | $5.20B derived: sum of 2 quarters · filed 2023-02-24 | $7.60B derived: sum of 3 quarters · filed 2023-02-24 | $2.80B 10-Q · filed 2022-11-03 | |
| 2021-09-30 | $2.40B 10-Q · filed 2021-11-05 | $4.80B derived: sum of 2 quarters · filed 2021-11-05 | $6.90B derived: sum of 3 quarters · filed 2021-11-05 | $9.00B derived: sum of 4 quarters · filed 2022-02-25 | |
| 2021-06-30 | $2.40B 10-Q · filed 2021-08-09 | $4.50B derived: sum of 2 quarters · filed 2021-08-09 | $6.60B derived: sum of 3 quarters · filed 2022-02-25 | $8.70B derived: sum of 4 quarters · filed 2022-02-25 | |
| 2021-03-31 | $2.10B 10-Q · filed 2021-08-09 | $1.80B 10-Q · filed 2021-05-05 | $4.20B derived: sum of 2 quarters · filed 2022-02-25 | $6.30B derived: sum of 3 quarters · filed 2022-02-25 | $8.20B derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-12-31 | $2.10B 10-K · filed 2022-02-25 | $2.30B 10-K · filed 2021-02-25 | $4.20B derived: sum of 2 quarters · filed 2022-02-25 | $6.10B derived: sum of 3 quarters · filed 2022-02-25 | $2.10B 10-Q · filed 2021-11-05 |
| 2020-09-30 | $2.10B 10-Q · filed 2020-11-05 | $4.00B derived: sum of 2 quarters · filed 2020-11-05 | $5.90B derived: sum of 3 quarters · filed 2020-11-05 | $8.60B derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-06-30 | $1.90B 10-Q · filed 2020-08-05 | $3.80B derived: sum of 2 quarters · filed 2020-08-05 | $6.50B derived: sum of 3 quarters · filed 2021-02-25 | ||
| 2020-03-31 | $1.90B 10-Q · filed 2020-05-06 | $4.60B derived: sum of 2 quarters · filed 2021-02-25 | |||
| 2019-12-31 | $2.70B 10-K · filed 2021-02-25 | ||||
| 2018-12-31 | $1.10B 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |